Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27263689 | 0.92 | LMNA (0.56) | LMNAALDH1A1MAPK1KDM4EMEN1 | |
| SCHEMBL26857514 | 0.83 | LMNA (0.40) | LMNAALDH1A1MAPK1PTGS2SMN1; SMN2 | |
| SCHEMBL27719001 | 0.80 | LMNA (0.49) | LMNAALDH1A1MAPK1KDM4EMEN1 | |
| SCHEMBL2574501 | 0.80 | LMNA (0.49) | LMNAALDH1A1MAPK1KDM4EMEN1 | |
| SCHEMBL21184203 | 0.78 | LMNA (0.64) | LMNAALDH1A1MAPK1KDM4EPTGS2 | |
| SCHEMBL27468745 | 0.76 | TPMT (0.48) | ALDH1A1KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL2917593 | 0.76 | LCK (0.54) | LMNAALDH1A1MAPK1KDM4EMEN1 | |
| SCHEMBL8358558 | 0.73 | LMNA (0.45) | LMNAALDH1A1MAPK1KDM4EMEN1 | |
| SCHEMBL11615862 | 0.72 | SMN1; SMN2 (0.46) | ALDH1A1MAPK1KDM4ETDP1HPGD | |
| SCHEMBL15836210 | 0.72 | LMNA (0.51) | LMNAALDH1A1MAPK1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BACE1, APP, BACE2 | LMNA 609/4885ALDH1A1 3847/4885MAPK1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.